Factors Associated with Bullous Pemphigoid After Immune Checkpoint Inhibitor Therapy: A Real-World Cohort Study

Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a morbid cutaneous immune-related adverse event with limited data on clinical predictors. We conducted a retrospective cohort study using the TriNetX research database of adults with malignancy receiving at least two ICI administrations. Among 96,405 ICI-treated patients, 317 (0.33%) developed BP within 3 years of ICI initiation at a median of 375 days. Increased BP risk was associated with age 65–75 years (HR 2.14, 95% CI 1.6–2.9), age ≥75 years (HR 3.80, 2.8–5.2), male sex (HR 1.81, 1.4–2.4), renal cancer (HR 2.02, 1.4–3.0), bladder cancer (HR 1.94, 1.3–2.9), cutaneous melanoma (HR 1.77, 1.2–2.6), head and neck cancers (HR 1.58, 1.0–2.5), and DPP-4 inhibitor exposure (HR 2.47, 1.3–4.6). These findings identify demographic, tumor-specific, and medication-associated factors associated with ICI-BP that may support earlier recognition and risk stratification.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Dermatology
Published
2026-11-21
DOI
https://doi.org/10.1093/ced/llag469
Primary Topic
Autoimmune Bullous Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Factors Associated with Bullous Pemphigoid After Immune Checkpoint Inhibitor Therapy: A Real-World Cohort Study

Eli Kasheri, Janellen Smith, Xiying Fan
Clinical and Experimental Dermatology
Autoimmune Bullous Skin Diseases
article

Factors Associated with Bullous Pemphigoid After Immune Checkpoint Inhibitor Therapy: A Real-World Cohort Study

Eli Kasheri, Janellen Smith, Xiying Fan
article en

Abstract

Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a morbid cutaneous immune-related adverse event with limited data on clinical predictors. We conducted a retrospective cohort study using the TriNetX research database of adults with malignancy receiving at least two ICI administrations. Among 96,405 ICI-treated patients, 317 (0.33%) developed BP within 3 years of ICI initiation at a median of 375 days. Increased BP risk was associated with age 65–75 years (HR 2.14, 95% CI 1.6–2.9), age ≥75 years (HR 3.80, 2.8–5.2), male sex (HR 1.81, 1.4–2.4), renal cancer (HR 2.02, 1.4–3.0), bladder cancer (HR 1.94, 1.3–2.9), cutaneous melanoma (HR 1.77, 1.2–2.6), head and neck cancers (HR 1.58, 1.0–2.5), and DPP-4 inhibitor exposure (HR 2.47, 1.3–4.6). These findings identify demographic, tumor-specific, and medication-associated factors associated with ICI-BP that may support earlier recognition and risk stratification.

Clinical and Experimental Dermatology
University of California, Irvine (US)
Autoimmune Bullous Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon